Release of F from fluorhydroxyapatite (FHAp) during acid dissolution was studied to validate the use of this mineral as a plaque reservoir of F. FHAp minerals having a wide range of F concentrations were synthesised by aqueous precipitation, and samples repeatedly exposed to 50 mM lactic acid solution, pH 4.5, or similar lactic/acetic/formic acid mixtures, until dissolution was complete. While the Ca/P ratio in solution remained relatively constant and close to the ratio in the solid, the solution F/Ca ratio invariably changed during dissolution. During initial stages the F/Ca solution ratio was lower than in the solid but rose to reach a plateau higher than in the solid as dissolution progressed, an effect that was more pronounced with low-F FHAp. With these minerals the plateau F/Ca level never reached 0.2, suggesting that a F-enriched FHAp rather than pure fluorapatite precipitates during dissolution. It is concluded that a high-F FHAp mineral would best serve as an apatitic plaque reservoir of F

Keywords:
Dissolution, Fluorhydroxyapatite, Fluoride
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.